SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ADVENTRX Pharmaceuticals Inc (Anx)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: estatemakr who wrote (159)6/8/2007 2:45:33 PM
From: Keith Feral of 418
 
If we read between the lines with the correct rose colored glasses, we can clearly see that Cofactor will get direct approval from the phase 2b in Europe.<vbg>

The exciting thing is that this improvement in intravenous folate is so damned obvious. It's like CDMA vs. GSM - speed kills. The more MTHF that is concentrated at the intracellular level, the more 5FU can be attached to the replicating enzymes in the cancer cells. At the same time, higher concentrations of MTHF will improve cell recovery from the toxicity of 5FU and other toxic agents.

I wonder what the mouse models showed for toxicity when Cofactor was used with Avastin, compared to Leucovorin and Avastin.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News